Last updated: April 25, 2026
Who Supplies Betamethasone Dipropionate and Clotrimazole?
What suppliers provide betamethasone dipropionate?
Betamethasone dipropionate is manufactured by both branded and generic-active ingredient (API) producers across multiple supply tiers (API, intermediates, and finished-dose manufacturers). A practical supplier list for procurement typically starts with (1) API manufacturers that sell dimethasone dipropionate directly and (2) finished-dose manufacturers (FDF) that source the API and can supply finished product or co-packaged goods.
Common supplier pool (API and FDF procurement channels):
| Supplier type |
Supplier |
Typical commercial role |
Notes for procurement |
| API producer |
Chongqing Yaoyao Pharmaceutical |
API |
Widely listed in generic API catalogs; verify grade and documentation set per purchase order |
| API producer |
Hubei Ruitai Biotechnology |
API |
Often positioned for generic raw material supply; confirm cGMP status and DMF/CEP availability |
| API producer |
Jinan Daode Biological Engineering |
API |
API supplier channel; confirm assay, polymorph/particle specs, and residuals |
| API producer |
Liaoning Huabang Pharmaceutical |
API |
Raw-material supplier for steroid APIs; verify global regulatory documentation |
| API producer |
TRC Pharmaceutical |
API |
Specialty chemical trading/manufacturing channel; confirm registration and labeling needs |
| Finished-dose / branded manufacturing |
Bausch Health (brands vary by market) |
FDF supply |
For distribution, this is often the downstream manufacturer of topical steroid products |
| Finished-dose / regional manufacturers |
Local pharma manufacturers and contract packers |
FDF |
Used heavily where registration and local labeling matter more than API sourcing |
What suppliers provide clotrimazole?
Clotrimazole has a deeper supplier market than many single-molecule APIs due to its long clinical use and large OTC/generic footprint. Supplier lists usually split between (1) API producers and (2) finished-dose manufacturers of creams, pessaries, tablets, and sprays.
Common supplier pool (API and FDF procurement channels):
| Supplier type |
Supplier |
Typical commercial role |
Notes for procurement |
| API producer |
MediSun / Medisun Biotech (varies by listing) |
API |
Verify if the entity supplies API vs. intermediates and confirm specs |
| API producer |
Zhejiang Transfar Pharmaceutical |
API |
Often used for generic API sourcing; confirm regulatory documentation |
| API producer |
Hubei Ruitai Biotechnology |
API |
Often appears across multiple antifungal APIs; confirm DMF/CEP availability |
| API producer |
Shanghai Yuanye Bio-Technology |
API |
Research-grade and commercial chemistry channel varies; confirm GMP readiness |
| API producer |
Sichuan Xinxing Pharmaceutical |
API |
Check product form (powder grades), microbiology, and impurity profile |
| Finished-dose / branded manufacturing |
Bayer (market-dependent brands) |
FDF supply |
Source country differs by jurisdiction; verify tender-specific manufacturer of record |
| Finished-dose / regional manufacturers |
Local pharma manufacturers and contract packers |
FDF |
Common where local approvals, language labeling, and packaging are required |
How to shortlist suppliers for both APIs (procurement-ready checks)
For betamethasone dipropionate and clotrimazole, the procurement shortlist should be constrained by regulatory readiness, quality systems, and product specs. The decision filters below are the same for both molecules and reduce late-stage qualification risk.
1) Regulatory documentation
- CEP/DMF availability for the specific polymorph/form, if applicable.
- Evidence of GMP manufacturing for the API site (or equivalent quality system documentation).
- Batch documentation format alignment with your QA/QC workflow (CoA contents, impurity list, residual solvents, heavy metals, microbiological limits where relevant).
2) Material attributes
- Particle size distribution and polymorphic form (especially important for consistent dissolution and bio-performance).
- Assay and impurity profile matching your internal method or method validation approach.
- Residual solvent and elemental impurities aligned with ICH Q3D/Q3C expectations.
3) Supply chain and commercial terms
- Minimum order quantity, lead time, and packaging format (drums vs. bags).
- Temperature/humidity packaging constraints where specified by your stability program.
- Ability to support change control (scale-up, site transfers, vendor sub-tier changes).
Side-by-side: supplier landscape and how it affects sourcing
| Attribute |
Betamethasone dipropionate |
Clotrimazole |
| Market maturity |
Long-established steroid API; moderate supplier depth |
Very established; broad API and FDF supplier base |
| Typical procurement pathway |
API + formulation partner for topical generics |
API or direct FDF sourcing; often easier to switch between generic suppliers |
| Biggest qualification variable |
Polymorph and impurity control |
Impurity profile and consistent particle/DMC control across batches |
| Supply risk pattern |
Fewer qualified API suppliers for higher-grade requirements |
Lower supplier switching friction, but documentation consistency still matters |
Key Takeaways
- Both betamethasone dipropionate and clotrimazole have active global supplier networks across API and finished-dose channels.
- Shortlist suppliers by regulatory documentation (CEP/DMF or equivalent GMP evidence), then validate material attributes (assay, impurities, polymorph/particle profile, residuals).
- Clotrimazole sourcing typically has broader switching options than betamethasone dipropionate due to wider FDF and API availability.
FAQs
1) Are there single global suppliers for both betamethasone dipropionate and clotrimazole?
Yes, some companies list multiple APIs, but qualification should be done per molecule, per grade, and per manufacturing site.
2) Should procurement prefer API manufacturers or finished-dose manufacturers?
API sourcing fits when you have a formulation and registration plan; finished-dose sourcing fits when speed-to-market and local labeling are primary.
3) What documentation is essential before contracting an API supplier?
A GMP-quality package tied to the exact API grade plus batch CoA format and impurity/residual specs.
4) What quality attributes most often drive rejections for these APIs?
Inconsistent impurity profiles and specification drift in particle size/polymorphic form, depending on the dosage form.
5) Does supplier switching affect stability and regulatory filings?
Yes. Switching suppliers can change impurity profiles and physical attributes, requiring stability and bridging steps depending on your filing strategy.
References
[1] United States Food and Drug Administration (FDA). Drug approvals and databases (drug-related information and regulatory resources).
[2] European Medicines Agency (EMA). European public assessment reports and scientific guidance resources.
[3] International Council for Harmonisation (ICH). ICH Q3C, Q3D quality guidelines for impurities and elemental impurities.
[4] World Health Organization (WHO). WHO quality assurance guidance for pharmaceutical products.
